AI Summary & Key Takeaways
AI InsightConclusions: Although Down syndrome screening tests still have not proven the ultra-screen test has been shown to be comparable to the Triple test, while the earlier timing may be considered to be an advantage.
📌 3 Key Takeaways
Abstract
Objective: To determine Down syndrome risk combining biochemical markers, fetal nuchal translucency and maternal age and comparing results with the triple test. Study design: A total of 121 pregnant women seen at an outpatient clinic between February 1998 and October 2000 were included in the study. The maternal serum PAPP-A, free (-hCG and the ultrasonographic nuchal translucency measurements at 11-14 weeks were combined with the patient's age and pregnancy related Down syndrome risks were calculated using a special software program at the New. York NTD Laboratories. The triple test was performed at 16-18 weeks on the same patient group. Amniocentesis was performed on patients with positive screening results. Data for both groups was compared. Results: Risk positivity was 3.2%, specificity 96.6%, false positivity 3.3% and true negativity 100% using the Ultra-screen test. The Triple test resulted in 1.7% risk positivity, 98.3% specificity, 1.6% false positivity and 100% true negativity. Amniocentesis was performed on a total of 5 patients (one included and both groups) and all were reported as constitutional karyotypes. There was no statistically significant difference between the results of the two tests. Conclusions: Although Down syndrome screening tests still have not proven the ultra-screen test has been shown to be comparable to the Triple test, while the earlier timing may be considered to be an advantage.
Özet
Amaç: Down sendromu riskinin biyokimyasal markerlar, fetal ense ödemi ve anne yaşı kullanılarak belirlenmesi ve üçlü tarama testi ile karşılaştırılması. Çalışma deseni: Şubat 1998-Ekim 2000 tarihleri arası antenatal polikliniğimize başvuran 121 gebe Down sendromu riski açısından çalışmaya dahil edildi. Gebeliklerinin 11-14 haftaları arası maternal serum PAPP-A ve free (-hCG, fetal ultrasonografik marker olarakta Nuchal Translucency ölçüldü ve anne yaşı ile kombine edilerek New York NTD laboratuarlarında özel bir software programı ile gebeye özgü Down sendromu riski hesaplandı. Aynı gebelere 16-18. hafta arası Tripple test yapıldı. Test sonucu pozitif olanlara amniosentez yapıldı. Bulgular: Ultra-screen test ile risk pozitifliği %3.2, spesifitesi %96.6, gerçek negatiflik oranı %100 olarak hesaplandı. Tripple test ile spesifite %98.3, gerçek negatiflik %100 olarak hesaplandı. Amniosentez toplam beş hastaya yapıldı ve hepsi normal karyotip olarak rapor edildi. Sonuç: Henüz Down sendromu tarama testlerinin güvenirliliği istenen düzeye ulaşmamıştır. Ancak ultra-screen testin sağladığı zaman avatajı lehine bir parametre olarak yorumlanabilir.